Skip to main content
Top
Published in: Malaria Journal 1/2009

Open Access 01-12-2009 | Research

Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province, Cameroon

Authors: Collins Sayang, Mathieu Gausseres, Nicole Vernazza-Licht, Denis Malvy, Daniel Bley, Pascal Millet

Published in: Malaria Journal | Issue 1/2009

Login to get access

Abstract

Background

After adoption of artesunate-amodiaquine (AS/AQ) as first-line therapy for the treatment of uncomplicated malaria by the malaria control programme, this study was designed to assess the availability of anti-malarial drugs, treatment practices and acceptability of the new protocol by health professionals, in the urban health facilities and drugstores of Yaoundé city, Cameroon.

Methods

Between April and August 2005, retrospective and current information was collected by consulting registers and interviewing health practitioners in urban health facilities using a structured questionnaire.

Results

In 2005, twenty-seven trade-named drugs have been identified in drugstores; quinine tablets (300 mg) were the most affordable anti-malarial drugs. Chloroquine was restricted to food market places and no generic artemisinin derivative was available in public health centres. In public health facilities, 13.6% of health professionals were informed about the new guidelines; 73.5% supported the use of AS-AQ as first-line therapy. However, 38.6% apprehended its use due to adverse events attributed to amodiaquine. Malaria treatment was mainly based on the diagnosis of fever. Quinine (300 mg tablets) was the most commonly prescribed first-line anti-malarial drug in adults (44.5%) and pregnant women (52.5%). Artequin® was the most cited artemsinin-based combination therapy (ACT) (9.9%). Medical sales representatives were the main sources of information on anti-malarials.

Conclusion

The use of AS/AQ was not implemented in 2005 in Yaoundé, despite the wide range of anti-malarials and trade-named artemisinin derivatives available. Nevertheless, medical practitioners will support the use of this combination, when it is available in a paediatric formulation, at an affordable price. Training, information and participation of health professionals in decision-making is one of the key elements to improve adherence to new protocol guidelines. This baseline information will be useful to monitor progress in ACT implementation in Cameroon.
Literature
1.
go back to reference Basco LK, Foumane Ngane V, Ndounga M, Same-Ekobo A, Youmba JC, Okalla Abodo RT, Soula G: Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 2006, 75: 388-395.PubMed Basco LK, Foumane Ngane V, Ndounga M, Same-Ekobo A, Youmba JC, Okalla Abodo RT, Soula G: Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 2006, 75: 388-395.PubMed
2.
go back to reference World Health Organization: Position Paper of WHO Roll Back Malaria Department on Malaria treatment policy. Geneva. 2004, 10.1016/S0140-6736(04)17446-1. World Health Organization: Position Paper of WHO Roll Back Malaria Department on Malaria treatment policy. Geneva. 2004, 10.1016/S0140-6736(04)17446-1.
3.
go back to reference WHO/AFRO: Framework for developing, Implementing and Updating National Antimalarial Treatment Policy: A guide for Country Malaria Control Programmes. AFR/MAL/03.02. 2003, Malaria: Liaison Bulletin of the Malaria Programmes, 2: 1-4. WHO/AFRO: Framework for developing, Implementing and Updating National Antimalarial Treatment Policy: A guide for Country Malaria Control Programmes. AFR/MAL/03.02. 2003, Malaria: Liaison Bulletin of the Malaria Programmes, 2: 1-4.
5.
go back to reference Amexo M, Tolhurst R, Barnish G, Bates I: Malaria misdiagnosis: effects on the poor and vulnerable. The Lancet. 2004, 364: 1896-1898. 10.1016/0140-6736(92)93160-O.CrossRef Amexo M, Tolhurst R, Barnish G, Bates I: Malaria misdiagnosis: effects on the poor and vulnerable. The Lancet. 2004, 364: 1896-1898. 10.1016/0140-6736(92)93160-O.CrossRef
6.
go back to reference Redd SC, Bloland PB, Kazembe PN, Patrick E, Tembenu R, Campbell CC: Usefulness of clinical case-definitions in guiding therapy for African children with malaria or pneumonia. Lancet. 1992, 340: 1140-1143. 10.1136/bmj.328.7455.1511.CrossRefPubMed Redd SC, Bloland PB, Kazembe PN, Patrick E, Tembenu R, Campbell CC: Usefulness of clinical case-definitions in guiding therapy for African children with malaria or pneumonia. Lancet. 1992, 340: 1140-1143. 10.1136/bmj.328.7455.1511.CrossRefPubMed
8.
go back to reference Reyburn H, Ruanda J, Mwerinde O, Drakeley C: The contribution of microscopy to targeting anti-malarial treatment in a low transmission area of Tanzania. Malar J. 2006, 5: 1-4. 10.1186/1475-2875-5-4.CrossRef Reyburn H, Ruanda J, Mwerinde O, Drakeley C: The contribution of microscopy to targeting anti-malarial treatment in a low transmission area of Tanzania. Malar J. 2006, 5: 1-4. 10.1186/1475-2875-5-4.CrossRef
9.
go back to reference Ahmed ME, Youssif MA: Impact of the national protocol for malaria treatment on prescribing patterns in Gezira state, Sudan. East Mediterr Health J. 2004, 10: 566-572.PubMed Ahmed ME, Youssif MA: Impact of the national protocol for malaria treatment on prescribing patterns in Gezira state, Sudan. East Mediterr Health J. 2004, 10: 566-572.PubMed
10.
go back to reference Phillips-Howard PA, Wannemuehler KA, Ter Kuile FO, Hawley WA, Kolczak MS, Odhacha A, Vulule JM, Nahlen BL: Diagnosis and prescribing practices in peripheral health facilities in rural western Kenya. Am J Trop Med Hyg. 2003, 68: 44-49. 10.1136/bmj.331.7519.734.PubMed Phillips-Howard PA, Wannemuehler KA, Ter Kuile FO, Hawley WA, Kolczak MS, Odhacha A, Vulule JM, Nahlen BL: Diagnosis and prescribing practices in peripheral health facilities in rural western Kenya. Am J Trop Med Hyg. 2003, 68: 44-49. 10.1136/bmj.331.7519.734.PubMed
11.
go back to reference Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW: Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ. 2005, 331: 706-707. 10.1007/BF00156827.CrossRef Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW: Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ. 2005, 331: 706-707. 10.1007/BF00156827.CrossRef
12.
go back to reference Ndumbe PM: Curative and preventive treatment of uncomplicated malaria in public health institutions in Cameroon. Eur J Epidemiol. 1989, 5: 183-188. 10.1007/BF00156827.CrossRefPubMed Ndumbe PM: Curative and preventive treatment of uncomplicated malaria in public health institutions in Cameroon. Eur J Epidemiol. 1989, 5: 183-188. 10.1007/BF00156827.CrossRefPubMed
Metadata
Title
Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province, Cameroon
Authors
Collins Sayang
Mathieu Gausseres
Nicole Vernazza-Licht
Denis Malvy
Daniel Bley
Pascal Millet
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2009
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-8-176

Other articles of this Issue 1/2009

Malaria Journal 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.